NCT02958085View on ClinicalTrials.gov

Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

November 4, 2016

Primary Completion Date

January 24, 2018

Study Completion Date

January 24, 2018

Conditions
Metabolism and Nutrition DisorderObesity
Interventions
DRUG

NNC0174-0833

Doses of NNC0174-0833, dosed either once daily or once weekly

DRUG

Placebo

Dosed either once daily or once weekly

Trial Locations (1)

66212

Novo Nordisk Investigational Site, Overland Park

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY